Table of Contents
<< Previous Issue | Mar 2022 (Vol: 2022, Issue: 3) | Next Issue >> |
- Section: Licensing
-
Endpoint Health and Grifols Collaborate to Develop Antithrombin III for Sepsis
-
Novartis Delves Further into AAV Gene Therapies with US$1.65 B Voyager Deal
-
Sanofi Enters Multi-Billion Dollar Antibody Deals with Adagene and IGM
- Section: Mergers & Acquisitions
-
Biocon Biologics Acquires Viatris’ Biosimilar Portfolio for US$3.3 B
- Section: Opinion & Analysis
-
IQVIA Pharma Deals Review of 2021
- Section: Research & Development
-
Bristol Myers Squibb Signs US$1.1 B Metastatic Cancer Pact with Volastra